JBIO
Jade Biosciences, Inc.·Healthcare
21.50
0.967%(−0.21)
Close PriceLast Updated: — ET
52W L: $6.5752W H: $28.00
JBIO NEWS
globenewswire.com
1d ago
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“the Company” or “Jade”), (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the first participant has been dosed in a first-in-human (FIH) Phase 1 clinical trial of JADE201. JADE201 is an investigational, half-life extended, afucosylated monoclonal antibody targeting the B cell activating factor receptor (BAFF-R) designed to deplete B cells through a dual mechanism of action: enhanced antibody effector function and BAFF signal blockade. The Company expects interim FIH data in 2027.
globenewswire.com
1d ago
Jade Biosciences Announces First Participant Dosed in First-in-Human Phase 1 Clinical Trial of JADE201, a Novel Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody
Interim Phase 1 data in rheumatoid arthritis expected in 2027 are anticipated to inform indication prioritization across multiple potential autoimmune indications supported by BAFF-R biology JADE201 preclinical data demonstrated dose-dependent BAFF-R occupancy, an extended half-life, and sustained B cell depletion in non-human primates SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc.
globenewswire.com
1d ago
Jade Biosciences Announces First Participant Dosed in Phase 2 JUNIPER Clinical Trial of JADE101 in IgA Nephropathy
SAN FRANCISCO and VANCOUVER, British Columbia, May 26, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (the “Company” or “Jade”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that the first participant has been dosed in JUNIPER, the Company's Phase 2 trial evaluating JADE101 in participants with immunoglobulin A nephropathy (IgAN). JADE101 is designed with ultra-high binding affinity to selectively block APRIL, a key driver of pathogenic IgA production in IgAN, a chronic autoimmune disease that frequently affects young adults and can lead to end-stage kidney disease over a patient's lifetime. Interim data from JUNIPER are expected in 2027.
globenewswire.com
May 7
Jade Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Update
SAN FRANCISCO and VANCOUVER, British Columbia, May 07, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced financial results for the first quarter ending March 31, 2026, and provided a corporate update.
globenewswire.com
Apr 23
Jade Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO and VANCOUVER, British Columbia, April 23, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced that Jade's Board of Directors granted an equity award to Edward R. Conner, M.D.
globenewswire.com
Apr 22
Jade Biosciences Appoints Edward R. Conner, M.D.
SAN FRANCISCO and VANCOUVER, British Columbia, April 22, 2026 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade” or the “Company”) (Nasdaq: JBIO), a clinical-stage biotechnology company focused on developing best-in-class therapies for autoimmune diseases, today announced the appointment of Edward R. Conner, M.D.
